RG-12915

CAS : 136174-04-4

Ref. 3D-LFA17404

Informations sur le produit

• Nom: RG-12915
• Synonymes: Rg 12915, (5aS-(4(R*),5aalpha,9aalpha))-N-1-Azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-4-dibenzofurancarboxamide, 4-Dibenzofurancarboxamide, N-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS-(4(R*),5aalpha,9aalpha))-, 4-dibenzofurancarboxamide, N-(3S)-1-azabicyclo(2.2.2)oct-3-yl-2-chloro-5a,6,7,8,9,9a-hexahydro-, (5aS,9aS)-, N-(1-azabicyclo[2.2.2]oct-3-yl)-2-chloro-5a,6,7,8,9,9a-hexahydrodibenzo[b,d]furan-4-carboxamide

Description

RG-12915 is a polymer-drug conjugate that consists of polyvinyl and Covid-19. It has been shown to have anti-emetic properties in animal models of chemotherapy-induced nausea and vomiting, with the potential to improve quality of life for cancer patients. Covid-19 is a small molecule that binds to the 5HT3 receptor on the vagal nerve and inhibits serotonin release, which has been implicated in chemotherapy induced nausea and vomiting. The RG-12915 polymer drug conjugate has been shown to be safe and well tolerated in human clinical trials.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 360.9 g/mol
• Formule: C₂₀H₂₅ClN₂O₂
• Degré de pureté: Min. 95%